Literature DB >> 27623929

Oleoylethanolamine and palmitoylethanolamine modulate intestinal permeability in vitro via TRPV1 and PPARα.

Mustafa A Karwad1, Tara Macpherson2, Bo Wang2, Elena Theophilidou1, Sarir Sarmad3, David A Barrett3, Michael Larvin4,5, Karen L Wright2, Jonathan N Lund1, Saoirse E O'Sullivan6.   

Abstract

Cannabinoids modulate intestinal permeability through cannabinoid receptor 1 (CB1). The endocannabinoid-like compounds oleoylethanolamine (OEA) and palmitoylethanolamine (PEA) play an important role in digestive regulation, and we hypothesized they would also modulate intestinal permeability. Transepithelial electrical resistance (TEER) was measured in human Caco-2 cells to assess permeability after application of OEA and PEA and relevant antagonists. Cells treated with OEA and PEA were stained for cytoskeletal F-actin changes and lysed for immunoassay. OEA and PEA were measured by liquid chromatography-tandem mass spectrometry. OEA (applied apically, logEC50 -5.4) and PEA (basolaterally, logEC50 -4.9; apically logEC50 -5.3) increased Caco-2 resistance by 20-30% via transient receptor potential vanilloid (TRPV)-1 and peroxisome proliferator-activated receptor (PPAR)-α. Preventing their degradation (by inhibiting fatty acid amide hydrolase) enhanced the effects of OEA and PEA. OEA and PEA induced cytoskeletal changes and activated focal adhesion kinase and ERKs 1/2, and decreased Src kinases and aquaporins 3 and 4. In Caco-2 cells treated with IFNγ and TNFα, OEA (via TRPV1) and PEA (via PPARα) prevented or reversed the cytokine-induced increased permeability compared to vehicle (0.1% ethanol). PEA (basolateral) also reversed increased permeability when added 48 or 72 h after cytokines (P < 0.001, via PPARα). Cellular and secreted levels of OEA and PEA (P < 0.001-0.001) were increased in response to inflammatory mediators. OEA and PEA have endogenous roles and potential therapeutic applications in conditions of intestinal hyperpermeability and inflammation.-Karwad, M. A., Macpherson, T., Wang, B., Theophilidou, E., Sarmad, S., Barrett, D. A., Larvin, M., Wright, K. L., Lund, J. N., O'Sullivan, S. E. Oleoylethanolamine and palmitoylethanolamine modulate intestinal permeability in vitro via TRPV1 and PPARα. © FASEB.

Entities:  

Keywords:  cannabinoid; gut; nuclear receptor

Mesh:

Substances:

Year:  2016        PMID: 27623929     DOI: 10.1096/fj.201500132

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  37 in total

1.  Interferon γ treatment increases endocannabinoid and related N-acylethanolamine levels in T84 human colon carcinoma cells.

Authors:  Mireille Alhouayek; Linda Rankin; Sandra Gouveia-Figueira; Christopher J Fowler
Journal:  Br J Pharmacol       Date:  2018-02-05       Impact factor: 8.739

2.  Impact of circadian rhythmicity and sleep restriction on circulating endocannabinoid (eCB) N-arachidonoylethanolamine (anandamide).

Authors:  Erin C Hanlon
Journal:  Psychoneuroendocrinology       Date:  2019-10-04       Impact factor: 4.905

3.  Localization of cannabinoid receptors CB1, CB2, GPR55, and PPARα in the canine gastrointestinal tract.

Authors:  Giorgia Galiazzo; Fiorella Giancola; Agnese Stanzani; Federico Fracassi; Chiara Bernardini; Monica Forni; Marco Pietra; Roberto Chiocchetti
Journal:  Histochem Cell Biol       Date:  2018-06-07       Impact factor: 4.304

Review 4.  Polarity scaffolds signaling in epithelial cell permeability.

Authors:  Lauren F O'Leary; Andrea M Tomko; Denis J Dupré
Journal:  Inflamm Res       Date:  2021-03-15       Impact factor: 4.575

Review 5.  New approaches and challenges to targeting the endocannabinoid system.

Authors:  Vincenzo Di Marzo
Journal:  Nat Rev Drug Discov       Date:  2018-08-17       Impact factor: 84.694

6.  Germ-free mice exhibit profound gut microbiota-dependent alterations of intestinal endocannabinoidome signaling.

Authors:  Claudia Manca; Besma Boubertakh; Nadine Leblanc; Thomas Deschênes; Sebastien Lacroix; Cyril Martin; Alain Houde; Alain Veilleux; Nicolas Flamand; Giulio G Muccioli; Frédéric Raymond; Patrice D Cani; Vincenzo Di Marzo; Cristoforo Silvestri
Journal:  J Lipid Res       Date:  2019-11-05       Impact factor: 5.922

Review 7.  The Expanded Endocannabinoid System/Endocannabinoidome as a Potential Target for Treating Diabetes Mellitus.

Authors:  Alain Veilleux; Vincenzo Di Marzo; Cristoforo Silvestri
Journal:  Curr Diab Rep       Date:  2019-11-04       Impact factor: 4.810

Review 8.  Neuroimmune signaling in alcohol use disorder.

Authors:  Emma K Erickson; Emily K Grantham; Anna S Warden; R A Harris
Journal:  Pharmacol Biochem Behav       Date:  2018-12-24       Impact factor: 3.533

9.  Alcohol binge disrupts the rat intestinal barrier: the partial protective role of oleoylethanolamide.

Authors:  M Antón; A Rodríguez-González; A Ballesta; N González; A Del Pozo; F R de Fonseca; M L Gómez-Lus; J C Leza; B García-Bueno; J R Caso; L Orio
Journal:  Br J Pharmacol       Date:  2018-10-29       Impact factor: 8.739

10.  Oleoylethanolamide differentially regulates glycerolipid synthesis and lipoprotein secretion in intestine and liver.

Authors:  Xiaoyue Pan; Gary J Schwartz; M Mahmood Hussain
Journal:  J Lipid Res       Date:  2018-10-28       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.